Cisapride is a new gastrointestinal prokinetic substance that is devoid of antidopaminergic and direct muscarinic activity. This was evidenced by a lack of effect on prolactin release and gastric secretion. In man, cisapride stimulates lower esophageal, gastric, small intestinal, and colonic motility. Accordingly, cisapride significantly improves esophageal reflux disorders, gastroparesis, and constipation and has been successfully used in the treatment of clinical conditions that result from a deficient motor coordination.
No takes yet. Share an insight, caveat, or question.
Reyntjens et al. (1986) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: